Human medicines European public assessment report (EPAR): Olumiant, baricitinib, Date of authorisation: 13/02/2017, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Kerendia, finerenone, Date of authorisation: 16/02/2022, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Oncaspar, pegaspargase, Date of authorisation: 14/01/2016, Revision: 20, Status: Authorised

List of industry subject matter experts and list of planned calls for industry subject matter experts

Record of data processing activity for Modelling and Simulation Pilot - Use of clinical study data for scientific advice

European Medicines Agency's data protection notice for Modelling and Simulation Pilot - Use of clinical study data for scientific advice

Minutes of PRAC meeting on 9-12 March 2026

NexoBrid

Opinion/decision on a Paediatric investigation plan (PIP): Lunsumio, mosunetuzumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000181993

EMA/PE/0000290054